Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Midtrimester abortion by intracervical prostaglandin E2.

S Stampe Sørensen, L Heisterberg, P Wolf

    European Journal of Obstetrics, Gynecology, and Reproductive Biology
    |March 1, 1986
    PubMed
    Summary

    Intracervical prostaglandin E2 (PGE2) gel is a safe and effective option for midtrimester abortion, showing higher completion rates and fewer side effects than prostaglandin F2 alpha (PGF2 alpha). This method offers advantages in managing second-trimester pregnancy termination.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Characterization of a fast transient outward current in neocortical neurons from epilepsy patients.

    Journal of neuroscience research·2004
    Same author

    Reflex writing seizures in two siblings with juvenile myoclonic epilepsy.

    Acta neurologica Scandinavica·2004
    Same author

    [Remarkable restricted tuberculosis epidemics in 2001/2002 in two Bavarian regions].

    Pneumologie (Stuttgart, Germany)·2004
    Same author

    Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment.

    The British journal of dermatology·2003
    Same author

    [Might it be epilepsy? What should the genera;l practitioner look out for in differential diagnosis].

    MMW Fortschritte der Medizin·2003
    Same author

    Stimulus-induced patterns of bioelectric activity in human neocortical tissue recorded by a voltage sensitive dye.

    Neuroscience·2003

    Area of Science:

    • Obstetrics and Gynecology
    • Reproductive Medicine
    • Pharmacology

    Background:

    • Midtrimester abortion induction requires effective and safe pharmacological agents.
    • Prostaglandins are commonly used, but their administration routes and efficacy vary.
    • Comparing different prostaglandin formulations and delivery methods is crucial for optimizing patient care.

    Purpose of the Study:

    • To compare the efficacy and safety of intracervical prostaglandin E2 (PGE2) gel versus intraamniotic prostaglandin F2 alpha (PGF2 alpha) for midtrimester abortion.
    • To evaluate key outcomes including success rate, induction-to-abortion interval, complication frequency, and side effects.

    Main Methods:

    • Randomized trial involving 76 patients undergoing midtrimester abortion.
    • Treatment groups received either intracervical/extraamniotic PGE2 gel or intraamniotic PGF2 alpha.

    Related Experiment Videos

  • Oxytocin augmentation, repeat PGE2 application, and potential second-day PGE2 administration were employed as needed.

    • Main Results:

    • No significant difference in success rate (93% PGE2 vs. 97% PGF2 alpha) or induction-to-abortion interval (16.8h PGE2 vs. 16.6h PGF2 alpha) within 48 hours.
    • PGE2 group demonstrated a statistically significant higher frequency of completed abortions.
    • PGE2 group experienced significantly lower gastrointestinal side effects, fewer complications, and reduced pethidine consumption.

    Conclusions:

    • Intracervical PGE2 gel is a viable and advantageous alternative to intraamniotic PGF2 alpha for midtrimester abortion.
    • The PGE2 gel method is safe, convenient, and equally easy to administer throughout the second trimester.
    • PGE2 gel offers improved outcomes regarding abortion completion and patient tolerance compared to PGF2 alpha.